Editorial board disclosure policy
(Last updated July 2020)
All editors responsible for recommending or making publication decisions are requested to disclose on an annual basis any potential conflict of interest, including current or recent financial relationships with any commercial entity whose products or services may be contained in the journal content.
The following competing interests were disclosed:
Guillaume Assie – Professor Assie has the following patent application EP17305968.4, 'Method for molecular typing of tumors in a single targeted next generation sequencing experiment'. He has received speaker's fees from Novartis and HRA-Pharma (all fees given to the Centre de Recherche Endocrinienne), and travel expenses from Novartis, HRA-Pharma and Ipsen.
Kare Birkeland – Prof Birkeland is employed by University of Oslo and Oslo University Hospital. He receives a yearly honorarium as Head of Medical Council, Norwegian Diabetes Association. He also receives an honorarium from Lifecare, a Norwegian company that is developing a glucose monitoring device. His employer receives research grants from the following pharmaceutical companies that I am lecturing for, participate in advisory boards with or participates in counselling activities: MSD, NovoNordisk, Lilly, Sanofi, Boehringer Ingelheim, AstraZeneca, Roche.
Cesar Luiz Boguszewski – Professor Boguszewski has received fees from Pfizer for being on the GH deficiency in adults advisory board. He has received honoraria from Novartis Oncologia, Pfizer and Ipsen for lecturing and consulting. He is a member of the editorial boards of the journals Endocrine and Archives of Endocrinology and Metabolism. He is a member of the Council of the Endocrine Society (Clinical Research Seat) and is Chair of the International Committee of the Brazilian Society of Endocrinology and Metabolism (SBEM).
Hedi Claahsen–van der Grinten – Dr Claahsen–van der Grinten is on the advisory boards of Spruce Biosciences and Neurocrine Biosciences, and is Head of the scientific committee of the I-CAH/DSD registry. She is an editorial board member of Pediatric Endocrinology Review and International Journal of Endocrinology.
Rossella Elisei – Professor Elisei is a consultant for the following companies: EISAI, Sanofi-Genzyme, EXELIXIS, Lilly, LOXO and IPSEN. She is a member of the Editorial Boards of Thyroid Journal and European Thyroid Journal.
Martin Fassnacht – Professor Fassnacht is a member of the Editorial Board of Journal of Clinical Endocrinology and Metabolism, Hormones and Cancer and Oncology Research and Treatment.
Maria Fleseriu – Professor Fleseriu has received research grants to the university as principal investigator, and occasional scientific consultant fees, from Chiasma, Crinetics, Ionis, Ipsen, Novo Nordisk, Novartis, Pfizer and Strongbridge. She is President of the Pituitary Society and Co-Chief Editor of Frontiers in Pituitary Endocrinology.
Laura Fugazzola – Professor Fugazzola has received personal fees from EISAI ltd and non-financial support from Sanofi-Genzyme.
Alessandra Gambineri – Associate Professor Gambineri has received personal consulting fees for Bayer and Aegerion Pharmaceuticals. She is an editorial board member for Journal of Endocrinology Investigation and L’ Endocrinologo.
Ken Ho – Professor Ho is on advisory boards and has received fees for acting so for Pfizer and Novartis. He has also received fees from Novo Nordisk and Versartis for research. He has received personal fees as a speaker from Pfizer and Ipsen. He is a member of the editorial board of Journal of the Endocrine Society and Pituitary.
Andrea Isidori – Professor Isidori has received unrestricted research grants from Novartis and Shire. He has also received travel expenses from IPSEN. He is Associate Editor for Endocrine (Springer Nature), on the Editorial Board of the Journal of Endocrinological Investigation, on the Executive Committee of the European Academy of Andrology, is Treasurer of the International Society of Andrology, on the Boards of the Italian Society of Andrology and Medical Sexology, and on the Scientific Committee of the Italian Society of Endocrinology.
Filip Knop – Within the past 36 months, FKK has received research support from Antag Therapeutics, AstraZeneca, Novo Nordisk, Sanofi and Zealand Pharma. FKK is co-founder of and a minority shareholder in Antag Therapeutics. He has also has served on scientific advisory panels and/or speaker's bureaus for and/or served as a consultant to Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Fractyl, Gubra, Merck Sharp & Dohme, Norgine, Novo Nordisk, Sanofi and Zealand Pharma. He has had travel expenses in connection with participation in scientific meetings and conferences being paid by AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk and Sanofi.
André Lacroix – Professor Lacroix is an Editor on the adrenal section of UpToDate and Encyclopedia of Endocrinology. He is an investigator, and on the advisory board and steering committee for clinical trials on Cushing’s syndrome with Novartis. He is an investigator Cortendo, Strongbridge clinical trials in Cushing’s syndrome. He has received speaker fees from Pfizer.
Bente Langdahl – Professor Langdahl has received financial support from Amgen and Novo Nordisk to her institutional account. She has received personal fess by acting on advisory boards and giving lectures from Amgen, UCB, Eli Lilly and TEVA. She is the Editor-in-Chief of Bone Reports, and is on the editorial boards of Bone, Calcified Tissue International, Osteoporosis and Sarcopenia and Osteoporosis International.
Juliane Léger – Professor Léger has the following conflicts of interest to declare: investigator in a clinical trial using growth hormone (GH) sponsored by Novo-Nordisk, support for travel to international meetings from several GH manufacturers (Ipsen, Mercks, Novo-Nordisk, Lilly) and fees for Ipsen pharma and Merck for lectures.
Markus J Seibel – Professor Seibel has received speaker fees and Advisory Board Honoraria from Amgen Australia. He is on the Publication Committee, ASBMR, and is an Editorial Board member for Calcified Tissue International, Osteology and Clinical Lab.
Robert Semple – Professor Semple has received non-financial support from Pfizer, as provision of sirolimus for the published PROMISE study of segmental overgrowth. He is an outgoing Associate Editor for Diabetologia, until January 2019, and outgoing Speciality Chief Editor, Frontiers in Endocrinology until March 2019.
Alice Sitch – Dr Sitch has a research grant from AstraZeneca. She has received travel and expenses to give a workshop at the International Society for Magnetic Resonance in Medicine (ISMRM), and is an Associate Editor for Trials.
Abd Tahrani – Professor Tahrani reports personal fees and non-financial support from Boehringer Ingelheim, Eli Lilly and AstraZeneca, personal fees from Bristol-Myers Squibb and Janssen, and grants from Novo Nordisk and Sanofi Aventis. He has also received equipment from Aptiva, Impeto Medical and ANSAR. He is a the Editor-in-Chief of European Endocrinology and Section Editor for Diabetes, Obesity and Metabolism, BMC Endocrine Disorders.
Jeremy Tomlinson – Professor Tomlinson has received research grants from Medical Research Council UK. He has received consultant fees from Poxel and Novonordisk. He is a member of the Editorial boards of Endocrine Connections and Journal of Steroid Biochemistry and Molecular Biology. He is also a Society for Endocrinology council and a member of clinical committee.
The following editors reported no competing interests:
- Taneli Raivio
- Roelof A J Smit
- W E Visser
- Zhengpei Zheng
Bioscientifica staff and freelancers working on the journal reported no conflicts of interest. Article authors' declarations are stated in each journal article. Referees must disclose any competing interests before agreeing to review any submission. For more information on the journal’s ethical policy, please read the ethical guidelines.
This policy follows the recommendations of the International Committee of Medical Journals Editors (ICMJE) and the Committee on Publication Ethics (COPE).